Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Jazz Pharmaceuticals Completes $820 Million Upfront Acquisition of Actio Biosciences

Jazz Pharmaceuticals Completes $820 Million Upfront Acquisition of Actio Biosciences

MT newswireMT newswire2026/09/15 14:16
10:16 AM EDT, 09/15/2026 (MT Newswires) -- Jazz Pharmaceuticals (JAZZ) has completed its acquisition of privately held Actio Biosciences for $820 million upfront, the company said Tuesday. The acquisition adds ABS-1230, a clinical-stage investigational therapy for KCNT1-related epilepsy, to Jazz Pharmaceuticals' pipeline. ABS-1230 is an oral, small-molecule KCNT1 inhibitor being developed for KCNT1-related epilepsy. Price: 244.75, Change: -1.12, Percent Change: -0.46
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Besenet: Supports the "$5,000 check" and it will not increase the deficit; Speaker of the House: Implementation of the plan will take time

US Treasury Secretary Janet Yellen stated that there are "ways" to implement the plan without increasing the deficit, but did not disclose specific cost-offset measures. She noted that the Treasury has studied this for "quite some time," and emphasized that "putting more money in Americans' pockets should be everyone's goal." House Speaker Mike Johnson said he had communicated with the President on this issue the previous night, but specific details have not yet been finalized, and it will take some time before the plan is implemented.

华尔街见闻2026/09/15 22:46